Georgia Capital Shareholder and Market Opportunity Overview
Private large
portfolio companies
EXTERNALLY VALUED
ӨӨ
08 RETAIL (PHARMACY) BUSINESS OVERVIEW (CONT'D)
GEORGIA
CAPITAL
REVENUE
AVERAGE BILL SIZE & NUMBER OF BILLS ISSUED
Margin enhancement and strong
growth in para-pharmacy sales
Strong sales in para-pharmacy products of
GEL 49.0 million in 1Q21 (up 18.0% y-o-y),
with 29.4% gross profit margin.
Para-pharmacy sales have the strongest
margins and the share of para-pharmacy
sales in retail revenue reached 34.8% in
1Q21 (30.1% in 1Q20).
Gross profit margin (%)
24.5%
25.5%
25.5%
25.4%
25.9% 23.2%
Number of bills issued, million
25.3
27.1
28.8
27.6
7.7
6.5
+10.5%
Same store growth (%)
NMF
9%
9%
6%
17%
-5%
800
679.4
614.7
GEL million
600
518.6
184.7
450.3
176.9
-0.7%
134.5
400
113.9
GEL
494.7
175.0
173.8
200
437.8
336.4
384.1
46.3
46.3
128.7
127.5
0
2017
2018
2019
2020
1Q20
1Q21
■Retail
Distribution
18.4
16.8
15.7
14.3
13.3
13.4
1Q21 CASH FLOW
HIGHLIGHTS
Number of pharmacies
countrywide
2017
2018
2019
2020
1Q20
1Q21
270
296
309
298
318
EBITDA1
CUSTOMER INTERACTIONS PER MONTH
GEL -2.5m
Operating leverage¹(%)
Operating cash flow¹
NMF
7.8%
4.1%
-1.4%
0.8%
-12.8%
c.0.8mln
EBITDA margin¹ (%)
8.6%
10.1%
10.6%
10.4%
10.6%
7.5%
Loyal customers
-19.3%
-68.1ppts y-o-y
EBITDA to cash conversion¹
GEL -5.1m
Free cash flow¹
Georgia Capital PLC | 1. Excluding IFRS16 impact
GEL million
150
100
+7.8%
70.4
65.3
52.2
38.9
50
-29.6%
18.6
13.1
million
10
20
2.1
2.3
2.4
2.3
2.6
2.2
0
0
2017
2018
2019
2020
1Q20
1Q21
2017
2018
2019
2020
1Q20
1Q21
49View entire presentation